Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People with solid tumour cancers that have come back or spread, who have already received appropriate standard treatment for their cancer type and stage, or where a clinical trial is considered the best next treatment option by the doctor in charge
• People whose cancer can be measured on scans, according to standard medical guidelines (known as RECIST v1.1)
• People who are generally well enough to carry out light activity and care for themselves (a standard health rating of 0 or 1 on a common medical scale)
• People with a life expectancy of at least 12 weeks
• People with adequate functioning of their bone marrow, liver, and kidneys, as defined by the trial protocol
• For certain parts of the trial: people with a confirmed diagnosis of breast cancer, ovarian cancer, biliary tract cancer (cancer of the bile ducts or gallbladder), endometrial cancer, or squamous non-small cell lung cancer that has spread or come back
• For certain parts of the trial: people weighing at least 30 kg
• For one specific part of the trial (Sub-Study 4 Part A): people whose cancer has progressed after at least one but no more than three prior treatment courses for metastatic or relapsed disease, with no satisfactory alternative treatment available as judged by the treating doctor

Who may not be able to join:

• People who have recently received certain cancer treatments before the trial starts, including: a type of chemotherapy called nitrosourea or mitomycin C within the past 6 weeks; experimental drugs from another clinical trial within the past 28 days or 5 half-lives (whichever is shorter); other chemotherapy within the past 21 days; non-chemotherapy cancer drugs within 21 days or 5 half-lives (whichever is shorter); or biological or immunotherapy treatments within the past 28 days
• People with compression of the spinal cord, or cancer that has spread to the membranes surrounding the brain or spinal cord
• People with cancer that has spread to the brain, unless it has been treated, is stable, causes no symptoms, and has not needed steroid medication above a certain dose for at least 4 weeks before the trial starts
• People with an active infection, including tuberculosis, hepatitis B, hepatitis C, or HIV
• People with a history of lung inflammation (not caused by infection) that needed steroid treatment, who currently have lung inflammation, or where lung inflammation cannot be ruled out on scans at the start of the trial
• People with serious lung problems caused by another ongoing lung illness
• People with certain heart conditions, including: significant irregular heartbeats; uncontrolled high blood pressure; a heart attack, unstable chest pain, or heart procedure (such as bypass surgery or a stent) within the past 6 months; a stroke, mini-stroke, or blood flow problems to the brain within the past 6 months; certain types of heart failure; a history of weakened heart muscle (cardiomyopathy); severe heart valve disease; an abnormal heart rhythm reading on an ECG above a certain level; or known risk factors for dangerous heart rhythm problems, including a family history of certain inherited heart conditions or unexplained sudden death in a family member under 40
• People with a history of, or signs suggesting, certain blood or bone marrow disorders (myelodysplastic syndrome or acute myeloid leukaemia)
• For Sub-Study 2: people who had a blood clot within 3 months before starting the trial (note: this criterion is no longer in effect following a protocol update — confirm with trial site); people who had to permanently stop a previous immunotherapy due to side effects; people with active or previously documented autoimmune or inflammatory conditions requiring ongoing steroid or immune-suppressing treatment; or people with a history of organ transplant
• For Sub-Study 2 Part B: people who have previously received a specific type of cancer treatment known as a TOP1 inhibitor (for example, irinotecan, topotecan, or trastuzumab deruxtecan)
• For Sub-Study 3: people currently taking medications or herbal supplements that strongly affect how the body processes certain drugs (strong CYP3A4 inducers or inhibitors — confirm with trial site); people with a history of a long-lasting severe drop in blood cell counts (lasting more than 2 weeks); people with a known tendency to bleed; people who have ongoing severe nausea and vomiting, chronic gut conditions, difficulty swallowing, or who have had significant bowel surgery that might affect how the study drug is absorbed; or people who have previously received a TOP1 inhibitor treatment
• For Sub-Study 4: people who have previously received the study drug AZD9574, or more than one course of another PARP inhibitor-based treatment; people currently taking medications or herbal supplements that strongly affect drug processing (strong CYP3A4 inducers or inhibitors — confirm with trial site); people who have previously received a specific immunotherapy drug used in this trial (rilvegostomig), for the relevant treatment group; people who have previously received a TOP1 inhibitor treatment; or people with ongoing severe nausea and vomiting, chronic gut conditions, difficulty swallowing, or significant bowel surgery that might affect absorption of the study drug

Important: Always verify eligibility with the trial site directly before applying.